The New Era of Immunotherapy in Bile Duct Cancer Management
Bile duct carcinoma or well known as cholangiocarcinoma (CCA) is the second most common of primary liver malignancy after hepatocellular carcinoma (HCC). Although cholangiocarcinoma is a rare cancer, it has an aggressive feature with very poor prognosis. The epidemiological profile of cholangiocarci...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2020
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/74090 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: The New Era of Immunotherapy in Bile Duct Cancer Management
- Optimising Therapeutic Options for Bile Duct Cancer in the Era of Molecular Profiling, Immunotherapy and Pharmacogenomics
- Bile Duct Stones
- Liver Transplantation and Endoscopic Management of Bile Duct Complications
- Bile Duct Paucity in Infancy
- Bile Duct Cancer: From Bench to Bedside – Latest Developments
- Gallbladder and Bile Ducts: Anatomical Structures and Clinical Associations for 2025